VEGF-R1 May Predict Response to Peptide Radionuclide Therapy in Neuroendocrine Tumors
In 40 neuroendocrine tumor patients who completed PRRT, VEGF-R1 levels decreased significantly after treatment and showed the best discriminatory ability (AUC 0.7) for identifying treatment responders among the angiogenic biomarkers tested.
Quick Facts
What This Study Found
After four PRRT cycles in 40 NET patients, CgA, VEGF-R1, and VEGF-R2 decreased significantly while VEGF-R3 increased. VEGF levels were unchanged. VEGF-R1 had the best discriminatory value for treatment response (AUC 0.7).
Key Numbers
NETs are characterized by rich vascularization. PRRT uses radiolabeled peptides targeting somatostatin receptors.
How They Did This
Prospective cohort of 40 patients with gastro-entero-pancreatic and broncho-pulmonary neuroendocrine tumors who completed four cycles of PRRT. Serum CgA, VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 measured by ELISA before and after treatment. AUROC analysis assessed biomarker discriminatory ability for treatment response.
Why This Research Matters
PRRT uses radiolabeled somatostatin peptide analogs to target tumors, but predicting which patients will respond remains challenging. Identifying reliable blood biomarkers like VEGF-R1 could help clinicians monitor treatment effectiveness and potentially guide therapy decisions without waiting for imaging results.
The Bigger Picture
PRRT is a key peptide-based treatment for advanced neuroendocrine tumors, but monitoring tools are limited. This study adds VEGF-R1 to the list of potential response biomarkers, complementing traditional markers like chromogranin A and imaging. Better biomarkers could enable more personalized treatment approaches.
What This Study Doesn't Tell Us
Small sample size (40 patients) limits statistical power and generalizability. Single-center study. AUC of 0.7 indicates only moderate discriminatory ability. No comparison to imaging-based response assessment. Mixed GEP and BP NET types may mask tumor-specific biomarker patterns.
Questions This Raises
- ?Does combining VEGF-R1 with other biomarkers improve prediction of PRRT response beyond AUC 0.7?
- ?Are angiogenic biomarker changes different between GEP and broncho-pulmonary NETs?
- ?Could serial VEGF-R1 monitoring during PRRT cycles guide early therapy adjustments?
Trust & Context
- Key Stat:
- VEGF-R1 AUC: 0.7 Among five angiogenic biomarkers tested, VEGF-R1 showed the best ability to distinguish PRRT responders from non-responders in neuroendocrine tumor patients
- Evidence Grade:
- Rated preliminary: small cohort of 40 patients with moderate discriminatory findings (AUC 0.7). Needs larger validation studies before clinical adoption.
- Study Age:
- Published in 2024. Represents current biomarker research in the peptide radionuclide therapy field.
- Original Title:
- Angiogenic biomarkers of response to treatment with peptide receptor radionuclide therapy in neuroendocrine tumours.
- Published In:
- Endokrynologia Polska, 75(4), 412-418 (2024)
- Authors:
- Strzelczyk, Janusz, Wójcik-Giertuga, Monika, Makulik, Karolina, Rosiek, Violetta, Kamiński, Grzegorz, Kajdaniuk, Dariusz, Kos-Kudła, Beata
- Database ID:
- RPEP-09330
Evidence Hierarchy
Frequently Asked Questions
What is PRRT and how does it treat neuroendocrine tumors?
PRRT (peptide receptor radionuclide therapy) attaches a radioactive molecule to a peptide that targets somatostatin receptors on neuroendocrine tumors. The peptide delivers radiation directly to tumor cells, minimizing damage to healthy tissue. It's used for advanced tumors that express somatostatin receptors.
Can a blood test tell if PRRT is working?
This study suggests VEGF-R1, a protein involved in blood vessel growth, may help. Its levels dropped after PRRT in responders, with moderate accuracy (AUC 0.7) for predicting response. However, this needs confirmation in larger studies before it could replace imaging for monitoring treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09330APA
Strzelczyk, Janusz; Wójcik-Giertuga, Monika; Makulik, Karolina; Rosiek, Violetta; Kamiński, Grzegorz; Kajdaniuk, Dariusz; Kos-Kudła, Beata. (2024). Angiogenic biomarkers of response to treatment with peptide receptor radionuclide therapy in neuroendocrine tumours.. Endokrynologia Polska, 75(4), 412-418. https://doi.org/10.5603/ep.100241
MLA
Strzelczyk, Janusz, et al. "Angiogenic biomarkers of response to treatment with peptide receptor radionuclide therapy in neuroendocrine tumours.." Endokrynologia Polska, 2024. https://doi.org/10.5603/ep.100241
RethinkPeptides
RethinkPeptides Research Database. "Angiogenic biomarkers of response to treatment with peptide ..." RPEP-09330. Retrieved from https://rethinkpeptides.com/research/strzelczyk-2024-angiogenic-biomarkers-of-response
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.